BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12054061)

  • 1. Aripiprazole (Otsuka Pharmaceutical Co).
    Ozdemir V; Fourie J; Ozdener F
    Curr Opin Investig Drugs; 2002 Jan; 3(1):113-20. PubMed ID: 12054061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
    Nordquist RE; Risterucci C; Moreau JL; von Kienlin M; Künnecke B; Maco M; Freichel C; Riemer C; Spooren W
    Neuropharmacology; 2008 Feb; 54(2):405-16. PubMed ID: 18054053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perospirone (Sumitomo Pharmaceuticals).
    de Paulis T
    Curr Opin Investig Drugs; 2002 Jan; 3(1):121-9. PubMed ID: 12054062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine partial agonists: a new class of antipsychotic.
    Lieberman JA
    CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
    Etievant A; Bétry C; Arnt J; Haddjeri N
    Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aripiprazole: a new atypical antipsychotic drug].
    Fischer B; Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
    Kerpel-Fronius S; Lóránt M
    Neuropsychopharmacol Hung; 2004 Dec; 6(4):177-84. PubMed ID: 15825673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
    Bergman J
    Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole: pharmacology, efficacy, safety and tolerability.
    Kinghorn WA; McEvoy JP
    Expert Rev Neurother; 2005 May; 5(3):297-307. PubMed ID: 15938662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aripiprazole as "dopamine sensitivity stabilizer"].
    Tadokoro S
    Nihon Rinsho; 2013 Apr; 71(4):684-8. PubMed ID: 23678600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aripiprazole use in children and adolescent psychiatric patients].
    Chevreuil C; Polard E; Lemonnier E; Guillemot P; Bentué-Ferrer D;
    Therapie; 2011; 66(2):123-30. PubMed ID: 21635859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
    Hirose T; Kikuchi T
    J Med Invest; 2005 Nov; 52 Suppl():284-90. PubMed ID: 16366516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: a review of its pharmacology and clinical use.
    Taylor DM
    Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.